Local Expertise, Growing Oncology Market Behind Lilly/Innovent Deal
This article was originally published in PharmAsia News
Executive Summary
The deal just signed between Lilly and Innovent is one of the most wide-ranging so far between a US pharma major and a Chinese biotech, and has the dual attractions of accessing both local capabilities and the growing oncology market in China.